Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : TEVJF save search
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.4 0.53% 0.45% 26
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.1 0.99% -0.99% 5.3K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | News | $273.54 0.6% 0.65% 8.5K
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-11-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.4 0.53% 0.45% 26
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
KMDA | $5.1 0.99% -0.99% 5.3K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
avt05 simponi biosimilar positive results study
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Published: 2023-11-10 (Crawled : 14:30) - globenewswire.com
ALVO | $13.4 0.53% 0.45% 26
|
n/a
|
| O: 0.12%
H: 7.18%
C: 3.56%
KMDA | $5.1 0.99% -0.99% 5.3K
|
Health Technology
|
| O: -0.22%
H: 0.86%
C: 0.86%
biosimilar chmp positive stelara
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Published: 2022-09-30 (Crawled : 22:00) - prnewswire.com
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
macular positive results diabetic
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo positive cell carcinoma
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Published: 2022-07-14 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
Published: 2022-05-16 (Crawled : 13:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
avt04 stelara biosimilar positive
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published: 2022-01-19 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
dupixent trial positive phase 3
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Published: 2021-12-08 (Crawled : 23:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.62%
H: 2.7%
C: 2.42%
dupixent positive results children phase 3
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.